Shoshana Levy Department of Medicine, Division of Oncology, Stanford University, USA
2 protocols

Felipe Vences-Catalán Department of Medicine, Division of Oncology, Stanford University, USA
2 protocols

Minu K. Srivastava
  • Department of Medicine, Division of Oncology, Stanford University, USA
  • 1 Author merit

Education

Ph.D. in University of Maryland Baltimore County

Current position

Oncomed Pharmaceuticals

Publications

  1. Srivastava, M. K., Sinha, P., Clements, V. K., Rodriguez, P. and Ostrand-Rosenberg, S. (2010). Myeloid-derived suppressor cells inhibit T-cell activation by depleting cystine and cysteine. Cancer Res 70(1): 68-77.

  2. Srivastava, M. K., Bosch, J. J., Wilson, A. L., Edelman, M. J. and Ostrand-Rosenberg, S. (2010). MHC II lung cancer vaccines prime and boost tumor-specific CD4+ T cells that cross-react with multiple histologic subtypes of nonsmall cell lung cancer cells. Int J Cancer 127(11): 2612-2621.

  3. Bosch, J. J., Iheagwara, U. K., Reid, S., Srivastava, M. K., Wolf, J., Lotem, M., Ksander, B. R. and Ostrand-Rosenberg, S. (2010). Uveal melanoma cell-based vaccines express MHC II molecules that traffic via the endocytic and secretory pathways and activate CD8+ cytotoxic, tumor-specific T cells. Cancer Immunol Immunother 59(1): 103-112.

  4. Srivastava, M. K., Bosch, J. J., Thompson, J. A., Ksander, B. R., Edelman, M. J. and Ostrand-Rosenberg, S. (2008). Lung cancer patients' CD4(+) T cells are activated in vitro by MHC II cell-based vaccines despite the presence of myeloid-derived suppressor cells. Cancer Immunol Immunother 57(10): 1493-1504.

  5. Thompson, J. A., Srivastava, M. K., Bosch, J. J., Clements, V. K., Ksander, B. R. and Ostrand-Rosenberg, S. (2008). The absence of invariant chain in MHC II cancer vaccines enhances the activation of tumor-reactive type 1 CD4+ T lymphocytes. Cancer Immunol Immunother 57(3): 389-398.

  6. Bosch, J. J., Thompson, J. A., Srivastava, M. K., Iheagwara, U. K., Murray, T. G., Lotem, M., Ksander, B. R. and Ostrand-Rosenberg, S. (2007). MHC class II-transduced tumor cells originating in the immune-privileged eye prime and boost CD4(+) T lymphocytes that cross-react with primary and metastatic uveal melanoma cells. Cancer Res 67(9): 4499-4506.

1 Protocol published
Macrophage Polarization by Tumor-induced MDSCs Assay
Authors:  Felipe Vences-Catalán, Minu K. Srivastava and Shoshana Levy, date: 08/20/2016, view: 5472, Q&A: 0
Myeloid derived suppressor cells (MDSCs) are a subset of granulocytes (immature myeloid cells) that exploit a variety of mechanism to modulate the innate and adaptive immune system. MDSCs are present normally in the body, but their numbers increase ...
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.